Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lie Lin

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Cancer Medicine|April 19, 2022
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter studyYuchen Zhang, Panpan Liu, Jun Cai, et al.
NPJ Biofilms and Microbiomes|July 14, 2025
Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD miceSong-Xia Zhang, Fang-Fang Hu, Huan Chen, et al.
Oncology and Therapy|December 16, 2023
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase InhibitorsHong Chen, Yan Wen, Yun Zeng, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Leukemia|March 27, 2023
Validation of the imatinib-therapy failure modelXiaoshuai Zhang, Robert Peter Gale, Bingcheng Liu, et al.
Journal for Immunotherapy of Cancer|October 25, 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Cancer Medicine|April 19, 2022
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter studyYuchen Zhang, Panpan Liu, Jun Cai, et al.
NPJ Biofilms and Microbiomes|July 14, 2025
Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD miceSong-Xia Zhang, Fang-Fang Hu, Huan Chen, et al.
Oncology and Therapy|December 16, 2023
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase InhibitorsHong Chen, Yan Wen, Yun Zeng, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Leukemia|March 27, 2023
Validation of the imatinib-therapy failure modelXiaoshuai Zhang, Robert Peter Gale, Bingcheng Liu, et al.
Journal for Immunotherapy of Cancer|October 25, 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, et al.
Pageof 8